Tina quant hba1c gen 3 kit

Colorimetric assays were used to determine plasma levels of cholesterol (CHOL), triglycerides (TG) (Erba Lachema, Brno, Czech Republic) and free fatty acids (FFAs) (Roche, Mannheim, Germany). The plasma insulin concentration was determined using a radioimmunoassay (RIA) kit (Millipore, St. Charles, MI, USA). Leptin and fibroblast growth factor 21 (FGF21) were determined using mouse and rat enzyme-linked immunosorbent assay (ELISA) kits (Millipore, St. Charles, MI, USA). An ELISA immunoassay kit was used to determine plasma levels of glucagon (Merck, Darmstadt, Germany). Glycated hemoglobin (HbA1c) was determined using the Tina-quant HbA1c Gen. 3 kit (Roche, Mannheim, Germany). All measurements were performed according to the manufacturer’s instructions. The concentration of c-reactive protein (CRP) in fasting plasma was determined using a Mouse CRP ELISA kit (Thermo Scientific, Frederick, MD, USA).

Study participants were identified as diabetes or non-diabetes based on blood biomarkers (C-peptide, HbA1c, glucose), self-reported diabetes and self-reported administration of anti-diabetes medications. Serum C-peptide levels were determined by the sandwich electrochemiluminescence immunoassay using Elecsys C-Peptide kit (Roche, Basel, Switzerland), while HbA1c in blood was measured using turbidimetric inhibition immunoassay (TINIA) utilizing Tina-quant HbA1c Gen. 3 kit (Roche) on hemolyzed blood samples and random glucose levels in serum were measured using the enzymatic reference method with GLUC3 glucose hexokinase kit (Roche), utilizing a COBAS instrument (Roche).
We classified our study cohort based on the phenotypic data provided by QBB. We first identified T1DM as self-declared diabetes subjects receiving insulin treatment exclusively and with serum C-peptide levels < 0.5 ng/mL. Subjects who did not meet the criteria for T1DM were classified as T2DM if they met any of the following criteria: self-declared diabetes, self-reported diabetes medication or with HbA1c > 6.5%. Subjects who did not meet the T1DM or T2DM criteria were classified as non-diabetes subjects.